T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Main Street Capital
MAIN
$5.47B
| $32.5M | 0.01% |
989,472
+1,720
| +0.2% | +$54.8K |
|
|
BNCN
927
DELISTED
BNC Bancorp
BNCN
| $32.5M | 0.01% |
1,430,959
+820,259
| +134% | +$18.5M |
|
928
Black Hills Corp
BKH
$5.58B
| $32.4M | 0.01% |
514,376
-27,379
| -5% | -$1.65M |
|
929
Forestar Group
FOR
$1.49B
| $32.4M | 0.01% |
2,727,170
-442,840
| -14% | -$5.55M |
|
|
FOLD
930
DELISTED
Amicus Therapeutics
FOLD
| $32.1M | 0.01% |
5,883,948
-17,100
| -0.3% | -$120K |
|
931
Digital Realty Trust
DLR
$72.9B
| $32M | 0.01% |
294,039
+198,253
| +207% | +$18.8M |
|
932
Mohawk Industries
MHK
$9.27B
| $31.9M | 0.01% |
168,084
-3,450
| -2% | -$671K |
|
933
T. Rowe Price
TROW
$23.8B
| $31.8M | 0.01% |
436,294
+15,100
| +4% | +$1.12M |
|
|
BCR
934
DELISTED
CR Bard Inc.
BCR
| $31.8M | 0.01% |
135,049
+2,655
| +2% | +$577K |
|
935
Hawkins
HWKN
$2.7B
| $31.7M | 0.01% |
1,461,902
+13,400
| +0.9% | +$269K |
|
936
Employers Holdings
EIG
$864M
| $31.7M | 0.01% |
1,093,110
-1,700
| -0.2% | -$49.3K |
|
937
Realty Income
O
$59.2B
| $31.7M | 0.01% |
471,820
+23,117
| +5% | +$1.4M |
|
938
Fortune Brands Innovations
FBIN
$5.83B
| $31.5M | 0.01% |
636,176
+265,817
| +72% | +$13M |
|
939
HNI Corp
HNI
$3.55B
| $31.3M | 0.01% |
673,701
+626,311
| +1,322% | +$27.5M |
|
940
Bread Financial
BFH
$4.46B
| $31.3M | 0.01% |
199,969
-6,014
| -3% | -$1M |
|
941
W.W. Grainger
GWW
$61.5B
| $31.2M | 0.01% |
137,481
-11,290
| -8% | -$2.57M |
|
942
Ionis Pharmaceuticals
IONS
$9.39B
| $31.2M | 0.01% |
1,340,638
+26,410
| +2% | +$852K |
|
|
CHSP
943
DELISTED
Chesapeake Lodging Trust
CHSP
| $31.2M | 0.01% |
1,341,450
+10,320
| +0.8% | +$250K |
|
|
LM
944
DELISTED
Legg Mason, Inc.
LM
| $31.1M | 0.01% |
1,054,319
+410,031
| +64% | +$13.3M |
|
945
NewMarket
NEU
$8.59B
| $31.1M | 0.01% |
74,947
+798
| +1% | +$322K |
|
|
SRCI
946
DELISTED
SRC Energy Inc
SRCI
| $31M | 0.01% |
4,648,439
-3,275,591
| -41% | -$22.2M |
|
|
ENV
947
DELISTED
ENVESTNET, INC.
ENV
| $30.9M | 0.01% |
928,720
-18,350
| -2% | -$592K |
|
|
KNL
948
DELISTED
Knoll, Inc.
KNL
| $30.9M | 0.01% |
1,271,330
-1,402,170
| -52% | -$32.9M |
|
|
CSRA
949
DELISTED
CSRA Inc.
CSRA
| $30.6M | 0.01% |
1,307,039
+1,065,410
| +441% | +$26.8M |
|
950
WSFS Financial
WSFS
$4.15B
| $30.6M | 0.01% |
949,750
-400
| -0% | -$13.6K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.